Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
In the interim, Deepak Khanna will lead Human Health International.
Subscribe To Our Newsletter & Stay Updated
